ABBVIE

AbbVie to acquire Aliada Therapeutics for $1.4 billion, advancing ALIA-1758, an anti-pyroglutamate amyloid beta antibody for Alzheimer's disease, leveraging Aliada's BBB-crossing technology.

FDA approved Botox Cosmetic for improving moderate to severe platysma bands, marking its fourth aesthetic indication. It offers a nonsurgical, injectable solution for adults, with doses of 26, 31, or 36 units based on severity. Clinical trials showed significant satisfaction among patients. Allergan Aesthetics promotes education and rewards through its Allē program.

The biopharmaceutical industry saw a 2% upturn in aggregate market capitalization to $4.3 trillion in Q3 2024, driven by FDA approvals and interest rate cuts. Bristol-Myers Squibb, Gilead Sciences, Sanofi, AbbVie, and Alnylam Pharmaceuticals led with over 10% growth. Novo Nordisk and Merck faced declines due to FDA rejections and sales drops.

AbbVie to acquire Alzheimer’s biotech Aliada for $1.4B; Philips reduces sales forecast due to China market decline.

Brown Rudnick serves as day-to-day IP counsel for Aliada Therapeutics, involved in AbbVie's $1.4B acquisition of Aliada, focused on CNS disease therapies. The deal includes Aliada's lead asset, ALIA-1758, an Alzheimer's treatment antibody, and leverages Aliada's MODEL platform for R&D. Adam Schoen leads the Brown Rudnick team in this acquisition.

AbbVie's $1.4 billion acquisition of Aliada Therapeutics positions them to advance ALIA-1758, a potentially best-in-class Alzheimer's therapy using novel BBB-crossing technology. This strategic move into neuroscience aims to address critical unmet needs and sets AbbVie on the frontier of CNS innovation.

AbbVie's $1.4 billion acquisition of Aliada Therapeutics positions them to advance ALIA-1758, a potentially best-in-class Alzheimer's therapy using novel BBB-crossing technology. This strategic move into neuroscience aims to address critical unmet needs and sets AbbVie on the frontier of CNS innovation.

The Orphan Indication Drugs market, focusing on rare diseases, is driven by government support and investment, offering lucrative opportunities for pharmaceutical companies. Key players include Bristol-Myers Squibb, Roche, Novartis, and Johnson & Johnson. The market is segmented by type (biologics, non-biologics) and application (hospital pharmacy, retail pharmacy, online sales), with growth potential in both established and emerging markets.

Kivu Biosciences raised $92M in Series A to advance its ADC technology, aiming for more precise and stable drugs to reduce side effects, with plans for a solid tumor clinical trial in 2024. Novo Holdings led the round, joined by six other venture firms.

Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.